Gilead Sciences, INC 13F institutional holdings
Quarterly disclosures of US equity positions held by institutional managers with over $100 million under management.
NASDAQ
Gilead Sciences, Inc. reported 5 holdings worth $1.6B for the period ended June 30, 2026.
NASDAQ
Gilead Sciences reports $2.12 billion in equity holdings across six biotechnology investments as of March 31, 2026.
NASDAQ
Gilead Sciences, Inc. filed its Form 13F-HR, revealing $1.94 billion in equity holdings across six biotechnology companies as of December 31, 2025.
NASDAQ
Gilead Sciences, Inc. reported its institutional equity holdings for the quarter ended September 30, 2025, totaling $1.79 billion across nine positions.
NASDAQ
Gilead Sciences, Inc. filed its Q2 2025 Form 13F-HR, revealing over $1.28 billion in equity holdings across 14 biopharmaceutical companies.
NASDAQ
Gilead Sciences, Inc. discloses its holdings as of March 31, 2025, showcasing significant investments in various biotechnology companies.
NASDAQ
Gilead Sciences' latest 13F filing discloses its equity holdings as of December 31, 2024, showcasing significant investments in various biotechnology companies.